Abstract
Incorporating headache/migraine operative procedures into an existing surgical practice may be challenging at first but can ultimately be very rewarding. There are several key reasons that might motivate physicians to incorporate this treatment specialty into their practice. First, some physicians are lucky enough to have trained at the rare academic center where these operative procedures are routinely taught and have seen the often life-changing results that these patients experience. For many of these physicians, there is a natural tendency to recreate their mentor’s style of practice. Other physicians may have a clinical, intellectual, or technical interest in peripheral nerve surgery from experience in hand surgery, facial nerve reconstruction, or other peripheral nerve procedures. However, the epidemiology of migraines is downright daunting. It is one of only eight disease states known to affect more than 10% of the world’s population and afflicts almost one in five Americans. Therefore, it is likely that many doctors may have friends, family, or personal experience dealing with migraines/chronic headaches and understand first-hand the immense burden these conditions place on patients and their loved ones. For these physicians, a significant motivation may be the simple desire to help ease this suffering. Moreover, some clinicians may have patients from the more than 36 million migraine sufferers in the United States who are impacted physically, socially, and occupationally by this debilitating condition and whom that have expressed to them an interest in surgical treatment for their chronic headaches. Finally, still other physicians may simply want to create a niche for their practice by offering a unique set of surgical procedures to this large and underserved patient population.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Ducic I, Hartmann EC, Larson EE. Indications and outcomes for surgical treatment of patients with chronic migraine headaches caused by occipital neuralgia. Plast Reconstr Surg. 2009;123(5):1453–61.
Guyuron B, et al. Five-year outcome of surgical treatment of migraine headaches. Plast Reconstr Surg. 2011;127(2):603–8.
Burch RC, et al. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015;55(1):21–34.
Ford JH, et al. A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache. 2017;57(10):1532–44.
Lipton RB, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–9.
Dodick DW, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36.
Hu XH, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159(8):813–8.
Rosenberg J. Migraine has impact on both healthcare costs and lost productivity. Am J Manag Care. 2018. https://www.ajmc.com/newsroom/migraine-has-impact-on-both-healthcare-costs-and-lost-productivity.
Stewart WF, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290(18):2443–54.
Guyuron B, Tucker T, Kriegler J. Botulinum toxin A and migraine surgery. Plast Reconstr Surg. 2003;112(5 Suppl):171S–3S; discussion 174S–176S.
Guyuron B, et al. The current means for detection of migraine headache trigger sites. Plast Reconstr Surg. 2015;136(4):860–7.
Janis JE, Barker JC, Palettas M. Targeted peripheral nerve-directed onabotulinumtoxin a injection for effective long-term therapy for migraine headache. Plast Reconstr Surg Glob Open. 2017;5(3):e1270.
Nahabet E, Janis JE, Guyuron B. Neurotoxins: expanding uses of neuromodulators in medicine–headache. Plast Reconstr Surg. 2015;136(5 Suppl):104S–10S.
Liu MT, Armijo BS, Guyuron B. A comparison of outcome of surgical treatment of migraine headaches using a constellation of symptoms versus botulinum toxin type A to identify the trigger sites. Plast Reconstr Surg. 2012;129(2):413–9.
Nation KM, et al. Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: relevance to medication overuse headache. Cephalalgia. 2019;39(5):617–25.
Shibata Y, Ishiyama S, Matsushita A. White matter diffusion abnormalities in migraine and medication overuse headache: a 1.5-T tract-based spatial statistics study. Clin Neurol Neurosurg. 2018;174:167–73.
ASPS policy statement: migraine headache surgery, A.S.o.P. Surgery, Editor; 2018. https://www.plasticsurgery.org/Documents/Health-Policy/Positions/ASPS-Statement_Migraine-Headache-Surgery.pdf.
Faber C, et al. A socioeconomic analysis of surgical treatment of migraine headaches. Plast Reconstr Surg. 2012;129(4):871–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Appendix
Appendix
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Branch, D.A., Moore, J.B., Peled, Z.M. (2020). How to Start a Headache/Migraine Surgery Practice. In: Afifi, A., Peled, Z., Janis, J. (eds) Surgical Treatment of Chronic Headaches and Migraines. Springer, Cham. https://doi.org/10.1007/978-3-030-36794-7_14
Download citation
DOI: https://doi.org/10.1007/978-3-030-36794-7_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-36793-0
Online ISBN: 978-3-030-36794-7
eBook Packages: MedicineMedicine (R0)